Online inquiry

IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10138MR)

This product GTTS-WQ10138MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ10138MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9662MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ984MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ931MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ9947MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KBSA301
GTTS-WQ7374MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ10243MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LFB-R603
GTTS-WQ1608MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ10710MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA M-1095
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW